
Federal judge vacates HRSA limits on gender-affirming care in Ryan White HIV program
Key Takeaways
- A Massachusetts bench-trial decision in AAHIVM v. HRSA nullified FY2026 Ryan White grant conditions framing “biological integrity” and limiting support for gender dysphoria interventions in minors.
- The court set the terms aside entirely and issued a permanent injunction, precluding HRSA from imposing the same or comparable requirements on members of the suing provider groups.
A Massachusetts federal court threw out HRSA grant terms that kept Ryan White clinics from offering gender-affirming care to patients with HIV.
Clinics funded through the Ryan White
The case, American Academy of HIV Medicine (AAHIVM) v. Health Resources and Services Administration (HRSA), went to a bench trial in September. Beyond declaring the terms unlawful, the court set them aside entirely, a step Lambda Legal said means no federal funding stream can carry them. The judge also issued a permanent injunction against the terms, or comparable policies, for members of the provider groups that sued.According to Lambda Legal, that membership takes in nearly all of the nation's HIV clinicians.
"For transgender people living with HIV, being treated by a provider who respects them is what keeps them coming back for treatment," Jose Abrigo, HIV project director at Lambda Legal, said in the release. "This decision protects that relationship and lets our clients return to the work they were doing before these conditions arrived."
What the Ryan White grant terms required
HRSA added the language to its fiscal year 2026 General Terms and Conditions in March, stating specifically:
“Child protections, biological integrity, parental rights, and lawful use of funds: HRSA prioritizes safeguarding children’s health and safety by not supporting medical interventions for gender dysphoria in minors that lack a strong evidence base and applying sex-based definitions grounded in biological reality.”
Lambda Legal and Herbert Smith Freehills Kramer (US) LLP brought the suit for AAHIVM, the HIV Medicine Association (HIVMA), the International Association of Providers of AIDS Care (IAPAC) and several individual clinicians. The plaintiffs contended that HHS and HRSA overstepped the Ryan White statute and dropped a long-held agency position without adequately explaining why. They also raised First and Fifth Amendment claims, saying the terms required providers to endorse the government's stance on gender identity and treated transgender patients unequally.
The government countered in an October brief that HRSA was keeping Ryan White dollars within the scope Congress set, which it characterized as HIV/AIDS treatment. The news release did not include a response from HHS or HRSA.
In the latest and final ruling, US district judge William Young ended the 165-page ruling with a sharp rebuke of the terms. "They are based in animus, loathing, and discrimination," the court wrote. "They are contrary to the laws of this nation and cannot continue to stand."
What the ruling means for Ryan White providers and patients
The Ryan White program served nearly 602,000 clients
"Nearly half of AAHIVM members rely on Ryan White funding, and almost 50% of those members report providing gender-affirming medical care, a core medical service under the program's own framework," Bruce Packett, executive director of AAHIVM, said in the release. "Now, these clinicians no longer have to choose between federal compliance and their duty of care to their patients."
Melanie Thompson, M.D., an HIV physician in Atlanta and co-chair of the HIVMA Primary Care Guidance for People with HIV panel, said research shows that "comprehensive, patient-centered care, including gender-affirming care, is strongly associated with higher levels of care engagement and viral suppression for transgender people with HIV."
José M. Zuniga, Ph.D., M.P.H., president emeritus of IAPAC, said the court "rejected the idea that political ideology can decide which patients are worthy of care."
Related to this article








